Phase IV Clinical Study of Safety and Tolerability of Oral Xeloda (Capecitabine) in Adjuvant Treatment of Resected Cancer of the Colon

Trial Profile

Phase IV Clinical Study of Safety and Tolerability of Oral Xeloda (Capecitabine) in Adjuvant Treatment of Resected Cancer of the Colon

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Colon cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 02 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top